A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of 160 mg Enteric-coated Micronised Free Base Darapladib in Healthy Chinese Subjects.
Phase of Trial: Phase I
Latest Information Update: 22 May 2017
At a glance
- Drugs Darapladib (Primary)
- Indications Atherosclerosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 07 Jun 2017 Biomarkers information updated
- 09 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 09 Dec 2013 New trial record